In a recent decision, the US District Court of Appeals Upheld State’s Rights to Regulate 340B.Some key quotes from the ruling. First, the 340B Program is not “so pervasive . . . that Congress left no room for the States to supplement it.” Pharmacies have always been an essential part of the 340B Program. Yet,…
Rural Hospitals Rely on the 340B Drug Pricing Program by Craig Thompson, Missouri Independent September 12, 2023 Republished from the Missouri Independent. Find original article HERE. According to a recent report, roughly 35% of rural hospitals in Missouri are at risk of closing as a result of inadequate revenue and low financial reserves. This comes as…
On July 28 Community Voices for 340B submitted a response to Senators Thune, Stabenow, Capito, Baldwin, Moran, and Cardin’s request for information on the 340B Drug Discount Program. CV340B conducted independent analysis of the publicly available HRSA audit reports finding that covered entity compliance with the 340B program has improved by 41% over the past…
Providers March to Capitol Hill for Second Straight Year to ‘Defend 340B’ July 13, 2023 William Newton Read the full article: Providers March to Capitol Hill for Second Straight Year to Defend 340B reprint excerpt. Excerpted by Permission of 340B Report. On a sunny, humid, 92-degree afternoon in Washington, D.C., over 50 safety- net…
Federal Judges Issue Decisions Regarding Safety-Net Provider Drug Dispensing Methods Over the past two weeks, federal judges have issued decisions that directly impact the health and safety of underserved communities and the safety-net providers that serve them. Each decision regards whether safety-net providers are entitled to use pharmacies that are not located at the provider’s…
On August 11, Merck issued a letter announcing its policy to stop “voluntarily” providing 340B discounts to 340B hospitals on drugs dispensed at contract pharmacies unless the hospital provides 340B contract pharmacy claims data through the 340B ESPTM platform for both Medicaid and non-Medicaid claims. Merck joins seven other drug manufacturers that have adopted similar policies based on their…
On July 30, the U.S. District Court for the Southern District of Indiana held oral arguments in the case, Eli Lilly et al. v. Becerra et al., regarding the May 17 enforcement letter (“May 17 Letter”) that HRSA sent to Eli Lilly and other drug manufacturers informing them of HRSA’s formal determination that their actions to…
On July 27, the U.S. House of Representatives approved an amendment to the House Appropriations Labor, Health and Human Services legislation that supports agency action against manufacturers that are not honoring contract pharmacy arrangements. The amendment was approved as part of a funding package for the next fiscal year for many federal departments, including HHS. The…
On July 11, the U.S. House Appropriations Committee approved the fiscal year (FY) 2022 appropriations bill (the “Bill”) and accompanying report for the Department of Labor, HHS, Education, and Related Agencies. The accompanying report calls for HRSA to report on actions it is taking to (1) safeguard safety-net providers’ access to discounted drugs, including those dispensed at contract pharmacies, and…
340B Safety net providers laud the Secretary of Health and Human Services’ (HHS) appointment of the much-awaited 340B Alternative Dispute Resolution (ADR) Board on June 21, 2021. Members of the ADR Board will serve as ADR Panelists to resolve disputes between 340B safety-net providers and drug companies. Beginning in the summer of 2020, several drug manufacturers have…